The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy
Francesco Muntoni(Great Ormond Street Hospital), Alberto Dubrovsky, Harold Malone, Michael Rabbia, Monique M. Ryan(Royal Children's Hospital), Jochem Gokemeijer(Bristol-Myers Squibb (Germany)), Daniel Kukral, Malavi T. Madireddi(Bristol-Myers Squibb (United States)), Xiling Yuan(Bristol-Myers Squibb (United States)), Mathew T. Pletcher, Ming Chang, Lora Hamuro, Brenda Wong(Cincinnati Children's Hospital Medical Center), Anjaneya Chimalakonda, Lumelle A. Schneeweis(Bristol-Myers Squibb (Germany)), Hannah Staunton(Roche (United Kingdom)), Karl Yen(Vertex Pharmaceuticals (United States)), Giridhar Tirucherai(Bristol-Myers Squibb (United States)), Michael Gulianello, Nicole Hellbach, Clifford Bechtold, Juergen Dukart(Roche (Switzerland)), Michael K. Ahlijanian, Irvith M. Carvajal(Brigham and Women's Hospital), Valérie Cosson(Roche (Switzerland)), Roxana Donisa Dreghici(Roche (Switzerland)), Barry J. Byrne(University of Florida), Jere E. Meredith, Peter Hocknell, Hugh J. McMillan(Children's Hospital of Eastern Ontario), Leslie K. Jacobsen(Johns Hopkins University), Amita Bansal(Australian National University), Maitea Guridi(Roche (Switzerland)), Zhen Lou, J L Swain, Ginger Rakestraw, Kathryn R. Wagner(Kennedy Krieger Institute), Heidemarie Kletzl(Roche (Switzerland))
Cited by 23
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Improving genetic diagnosis in Mendelian disease with transcriptome sequencing
|Science Translational Medicine|2017|809
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573